CYP17A1 and polycystic ovary syndrome: In contrast, CYP17A1 gene expression in BM-hMSC-treated ovaries was significantly decreased (0.57 ± 0.23-fold) compared to untreated PCOS mouse ovaries, confirming the ability of hBM-MSCs to reverse the PCOS characteristics in this mouse model.